MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential

Rhea-AI Summary

MAIA (NYSE American: MAIA) reported additional insider open-market purchases and highlighted clinical progress for its small-molecule telomere-targeting therapy ateganosine.

Directors and officers acquired approximately 182,445 shares between Nov 21–28, 2025, and continue to hold 4,480,120 shares (12.95%) of the company. The company said ateganosine is advancing through mid‑ to late‑stage development with encouraging clinical signals in advanced non‑small cell lung cancer (NSCLC).

Positive

• Insider purchases of ~182,445 shares between Nov 21–28, 2025
• Directors and officers hold 4,480,120 shares (12.95%)
• Ateganosine advancing through mid‑ to late‑stage clinical development

Negative

• None.

Key Figures

Current price $1.38 Pre-news trading level from market_context

Volume today 1,958,664 shares Roughly 3.1x 20-day average volume of 630,824 shares

Insider purchases 182,445 shares CEO and board open‑market buys between Nov 21–28, 2025 per article

Insider ownership 4,480,120 shares (12.95%) Directors and officers’ holdings as stated in article

THIO-101 response rate 38% Phase 2 trial in third-line NSCLC from prior news summary

Overall survival 17.8 months Observed OS in THIO-101 to date from prior news summary

Long-term survivor 30 months (912 days) Single THIO-101 patient survival as of Sept 17, 2025

Distance from 52-week high -49.64% Price versus 52-week high of $2.74 before this article

Market Reality Check

$1.36 Last Close

Volume Volume 1958664 is about 3.1x the 20-day average of 630824, indicating elevated trading interest ahead of this insider-focused news. high

Technical Shares traded at $1.38, remaining below the $1.60 200-day moving average, suggesting a longer-term downtrend despite recent strength.

Peers on Argus

MAIA gained 2.22% while peers were mixed: BTAI up 2.34%, but CUE, PDSB, ARTV, and QNTM fell between -1.92% and -6.42%, pointing to stock-specific factors rather than a broad biotech move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 01	Insider purchases, data	Positive	+1.7%	CEO and directors bought shares and reiterated Phase 2 THIO-101 efficacy data.
Nov 21	Clinical update	Positive	+4.7%	SITC 2025 update on enrollment, Phase 3 screening, OS data, and Fast Track status.
Nov 20	Conference efficacy talk	Positive	-5.3%	CEO presented 38% response rate versus 6% third-line benchmarks and Fast Track plan.
Oct 27	Trial-in-progress poster	Positive	+4.9%	AACR-NCI-EORTC poster and first five Part C patients enrolled with reassuring safety.
Oct 23	ESMO survival update	Positive	+7.3%	ESMO data showing a THIO-101 patient with 30-month survival and ongoing trials.

Pattern Detected

Recent positive clinical and insider news generally coincided with positive price reactions, though one notable divergence occurred on strong efficacy data.

Recent Company History

Over the past few months, MAIA has repeatedly highlighted progress for ateganosine in advanced NSCLC. Updates included a 38% response rate and 17.8 months overall survival in the Phase 2 THIO-101 trial, Fast Track designation, and a reported patient with 30 months (912 days) survival. Insider open‑market purchases around late November 2025 were also disclosed. Today’s article reiterates these themes of insider accumulation and strengthening clinical signals as the program advances.

Market Pulse Summary

The stock surged +18.8% in the session following this news. A strong positive reaction aligns with the article’s focus on ongoing insider accumulation and previously reported clinical signals, such as the 38% response rate and 17.8 months overall survival in THIO-101. Past news with similar themes often saw constructive moves, though one event produced a negative reaction, underscoring that enthusiasm around advanced NSCLC data and ownership updates has at times been volatile.

Key Terms

telomere-targeting medical

"small molecule telomere-targeting cancer therapy by MAIA Biotechnology, Inc."

Telomere-targeting describes therapies or technologies designed to act on telomeres — the protective caps at the ends of chromosomes — or the enzymes that maintain them, with the goal of altering how cells age, divide, or die. Like repairing or shortening the plastic tip on a shoelace to change how long it lasts, these approaches can slow aging-related damage or stop cancer cells from multiplying; for investors, they signal high scientific promise but also long development timelines, regulatory risk, and potentially large market opportunity.

non-small cell lung cancer (NSCLC) medical

"for patients with advanced non-small cell lung cancer (NSCLC)."

A common group of lung cancers that arise from the lungs’ cell lining and grow in ways different from the faster-spreading “small cell” form; think of it as several related varieties of the same illness rather than one single disease. It matters to investors because diagnosis rates, new drugs, diagnostic tests, and clinical trial results for these cancers can drive large, sustained revenue opportunities and regulatory decisions that materially affect healthcare and biotech company valuations.

open-market purchases financial

"A recent round of open-market purchases marks another display of confidence"

Open-market purchases are when a company or institution buys its own shares or other securities using the public stock market rather than through a private deal. For investors this matters because such buying reduces the number of shares available, often boosting metrics like earnings per share and signaling management thinks the stock is undervalued, while also using cash that might otherwise fund growth or dividends — like a business buying back chips at the table to increase each remaining player's stake.

AI-generated analysis. Not financial advice.

CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- A recent round of open-market purchases marks another display of confidence as the small molecule telomere-targeting cancer therapy by MAIA Biotechnology, Inc. (NYSE American: MAIA) advances through mid- to late-stage clinical development. Newly filed disclosures show that CEO Dr. Vlad Vitoc and other board members acquired approximately 182,445 shares between November 21 and 28, 2025. Insiders’ participation has been viewed by the market as a strong signal of alignment, conviction, and belief in the long-term value creation potential of the ateganosine platform.

The latest insider buying arrives as ateganosine continues to deliver encouraging results. These outcomes have strengthened internal and external confidence that MAIA’s novel telomere-targeting approach may represent a meaningful new therapeutic pathway for patients with advanced non-small cell lung cancer (NSCLC).

Taken together—material insider buying at market prices, sustained insider participation across 2025 financings, and strengthening clinical signals—MAIA’s leadership continues to demonstrate a unified stance: confidence in the company’s strategy, confidence in ateganosine’s growing body of clinical evidence, and confidence in the opportunity ahead as the program advances toward later-stage development. To date, Directors and Officers hold 4,480,120 shares or 12.95% of the company.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

FAQ

How many shares did MAIA insiders buy between Nov 21 and Nov 28, 2025?

Insiders acquired approximately 182,445 shares in open‑market purchases between Nov 21 and Nov 28, 2025.

What percentage of MAIA does company leadership currently hold as of Dec 11, 2025?

Directors and officers hold 4,480,120 shares, representing 12.95% of the company.

What development stage is MAIA's ateganosine program in as of Dec 11, 2025?

Ateganosine is reported to be advancing through mid‑ to late‑stage clinical development for advanced NSCLC.

Does the insider buying signal management confidence in MAIA (MAIA) in 2025?

The recent open‑market purchases and sustained insider participation in 2025 financings are presented as a signal of management confidence.

What clinical indication is MAIA targeting with ateganosine?

Ateganosine is being developed for patients with advanced non‑small cell lung cancer (NSCLC).

Will the insider purchases immediately change MAIA's shareholder dilution or control?

The filings show insider purchases of existing shares; there is no disclosure of a new offering or immediate dilution in the announcement.